Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: gadodiamide

« Back to Dashboard
Gadodiamide is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for Generic Name: gadodiamide

Drug Master File Entries: 0
Suppliers / Packaging: see list17

Pharmacology for Ingredient: gadodiamide

Clinical Trials for: gadodiamide

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Status: Completed Condition: Chronic Kidney Disease; Renal Insufficiency

A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
Status: Completed Condition: Coronary Artery Disease

A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Status: Completed Condition: Renal Artery Stenosis

A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-Iliac Arteries While Using Gadodiamide
Status: Completed Condition: Aorto-Iliac Stenosis; Arterial Occlusive Diseases

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer
Status: Recruiting Condition: Health Status Unknown; Prostate Carcinoma

Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities
Status: Terminated Condition: Glioblastoma Multiforme

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
Status: Completed Condition: Brain Pathology

Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.
Status: Completed Condition: Peripheral Arterial Disease

Neurovascular Non Contrast-Enhanced MR Angiography at 3T
Status: Recruiting Condition: Neurovascular Diseases

Efficacy and Safety of Primovist in Chinese Patients
Status: Completed Condition: Known or Suspected Focal Liver Lesions

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
INJECTABLE;INJECTION020123-001Jan 8, 1993RXYes<disabled><disabled>
Ge Healthcare
INJECTABLE;INJECTION022066-002Sep 5, 2007RXYes<disabled><disabled>
Ge Healthcare
INJECTABLE;INJECTION022066-001Sep 5, 2007DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn